Lupin Q1 FY27 Concall: Record Quarter, Strong Pipeline and US Growth Opportunities

Key Highlights Lupin delivered a record Q1 FY27, with strong revenue and EBITDA growth. Management highlighted continued momentum in India, a robust US pipeline, and multiple medium-term growth opportunities, while cautioning that Q1 margins may not be sustainable. Financial & Business Update • Revenue: ₹8,277 Crore, up 32% YoY, the company's highest-ever quarterly revenue. • EBITDA: ₹2,464 Crore, up 50% YoY, with margin at a record 30%. • Gross Margin: 74.6% vs 71.3% YoY. • Net Cash: ₹2,831 Crore, even after the Visupharma acquisition. • India Revenue: ₹2,380 Crore, up 13.9% YoY; core prescription business grew 15.1%. • US Sales: $366 Million in Q1; FY27 guidance at $1.1–1.2 Billion. Growth Pipeline & Outlook • Lupin plans 50+ launches over the next 3 years, including 10 exclusive First-to-Files and around 5 biosimilars. • Apixaban 505(b)(2) approval is targeted around September 2026, with commercial launch targeted for summer 2027. • Semaglutide launch in India has started strongly, while Spiriva Respimat filing is targeted for FY27. • FY27 Revenue Growth guidance is high single digits, with EBITDA Margin around 25% and R&D spend at around 8% of sales. What It Means • Strong Q1 execution and a diversified pipeline support medium-term growth visibility. • Rising competition in Tolvaptan and Mirabegron could pressure US sales and margins. Market Impact Impact: Positive Record revenue and EBITDA, strong India growth, and a broad product pipeline are positive. However, management expects Q1's 30% EBITDA Margin to normalize toward 25% in FY27 amid pricing pressure and higher competition. Learning Outcome First-to-File (FTF) status can provide a generic drug manufacturer with an early-mover advantage when it is the first eligible applicant to file for certain products. The duration and value of this advantage depend on regulatory and competitive factors. $LUPIN